Securing the public good of health research and development for developing countries

Røttingen, John-Arne; Chamas, Claudia; Goyal, LC; Harb, Hilda L; Lagrada, Leizel P.; Mayosi, Bongani M.

doi:10.2471/blt.12.105460

Cited by 29 publications

(26 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inequalities in healthcare may be further exacerbated by the current intellectual property regime unless care is taken to ensure that knowledge produced through genomics research becomes a public good [3]. Furthermore, the limited biotechnology and information technology infrastructure in many African countries hinders the participation of researchers and clinicians in genomic medicine.…”

Section: The Problemsmentioning

confidence: 99%

Genomic medicine in Africa: promise, problems and prospects

Wonkam

Mayosi

2014

Genome Med

View full text Add to dashboard Cite

Section: The Problemsmentioning

confidence: 99%

Genomic medicine in Africa: promise, problems and prospects

Wonkam

Mayosi

2014

Genome Med

View full text Add to dashboard Cite

“…Against the background of these topical developments, one could have assumed that the German government's global health strategy, and particularly its target measure on global health governance, would make reference to the recommendations and the follow-up activities to the WHO CEWG Report (7, 21, 22) and to the debate on a global health agreement (17, 19, 23). It was the realization that health inequalities exist and that they are largely avoidable which triggered the ongoing debate about a global health agreement and the proposals to improve global health architecture.…”

Section: Lacking Behind the Global Health Debatesmentioning

confidence: 99%

The German government's global health strategy – a strategy also to support research and development for neglected diseases?

Fehr

Razum

2014

Global Health Action

View full text Add to dashboard Cite

Neglected tropical infectious diseases as well as rare diseases are characterized by structural research and development (R&D) deficits. The market fails for these disease groups. Consequently, to meet public health and individual patient needs, political decision makers have to develop strategies at national and international levels to make up for this R&D deficit. The German government recently published its first global health strategy. The strategy underlines the German government's commitment to strengthening global health governance. We find, however, that the strategy lacks behind the international public health endeavors for neglected diseases. It fails to make reference to the ongoing debate on a global health agreement. Neither does it outline a comprehensive national strategy to promote R&D into neglected diseases, which would integrate existing R&D activities in Germany and link up to the international debate on sustainable, needs-based R&D and affordable access. This despite the fact that only recently, in a consensus-building process, a National Plan of Action for rare diseases was successfully developed in Germany which could serve as a blueprint for a similar course of action for neglected diseases. We recommend that, without delay, a structured process be initiated in Germany to explore all options to promote R&D for neglected diseases, including a global health agreement.

show abstract

“…The CEWG recommendation for the establishment of an international treaty including mandatory financial contributions from WHO member states has not achieved widespread support. However, WHO member states have recently indicated support for establishing a fund with a voluntary financing model that would finance biomedical R&D based on the principles formulated by the CEWG, namely: de-linkage of the delivery price from R&D costs, the use of open knowledge innovation, and licensing for access [ 3 , 4 ]. Such principles would allow for lower cost and more efficient R&D centered on the needs and resources of the people who need them most.…”

mentioning

confidence: 99%